Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma
NCT04970251Completed
- Sponsor
- Siriraj Hospital
- Start
- Nov 2018
- Primary completion
- Mar 2021
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Open-label, single-arm trial of aflibercept in neovascular glaucoma (NVG), sponsored by Siriraj Hospital. Primary endpoint: Intraocular pressure at 36 months. Started Nov 2018; status: completed.
02
Drugs
aflibercept
03
Conditions
neovascular glaucoma (NVG)
Beyond the preview
Go deeper on NCT04970251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04970251.